Barry Cohen

Barry Cohen

Barry Cohen has nearly 30 years in communications and marketing, the majority in senior positions at three large international health care companies – Abbott Laboratories, Warner-Lambert (now part of Pfizer) and Bayer, Inc.

At Abbott, Cohen was a member of the company’s investor relations team, responsible for preparing all financial analyst presentations. He also oversaw the company’s award-winning annual and quarterly reports and was responsible for both the company’s investor seminar and annual shareholders’ meeting.

After relocating to Arizona, Cohen served as editor of M.D. News, a magazine for Phoenix-area physicians. Later he was a reporter for a weekly newspaper in a north Phoenix, where he specialized in business articles and profiles of local publicly traded companies.

To further his knowledge and understanding of financial markets, Cohen earned a series 7 broker’s license and was employed at Charles Schwab as a registered representative.  He returned to the communications field with CPRi Communications, where he wrote numerous case studies and bylined articles for the company’s clients in the health care information technology industry. Later, he worked for a Scottsdale, Ariz.-based investment bank preparing profiles of companies being offered for sale.

Recent Articles

Big Pharma Banking on New Cancer Treatment Approach to Boost Sales

GlaxoSmithKline, Eli Lilly and Novartis are among the companies studying epigenetics -- a new approach to fighting cancer that is already seeing some success.

Among Biotechs, Cubist Has Held its Own During Recent Downturn

Cubist has had several pieces of good news during the past quarter, including a promotion agreement and a settled patent dispute. However, it still needs more products.

Is it Time to Join CEO and Jump on Celgene Shares?

Bog Hugin, CEO of Celgene, recently bought 10,000 shares of his own company -- and for plenty of good reasons.

Campaign to Kill Medco-Express Scripts Deal Likely Futile

It's not very likely that major pharmaceuticals will be able to prevent Express Scripts from acquiring Medco. But they do have good reason to try.

Sides Form on Medco-Express Scripts Deal

With the Federal Trade Commission likely to give the deal a close eye, analysts and investors sound off varying degrees of optimism and pessimism about this venture.